NCT06032208Recruiting
An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
An Extension of an Interventional Study to Assess the Effect of Expanded Dialysis (HDx-Theranova) on Patient Reported Symptoms Using London Evaluation of Illness (LEVIL)
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 31 Aug 2023
- Start date
- 1 Mar 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Diseases
- Chronic kidney disease
- NCT number
- NCT06032208
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Mar 2024 to the primary completion date, 31 Dec 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving daily hemodialysis treatment
- Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months
Other illness
- Active infection (may enroll once infection is cleared)
- Visual impairment
- History of neurocognitive impairment
- History of stroke (CVA)
Who the study is looking for
- Conventional thrice weekly HD schedule
- Must be on chronic hemodialysis for at least 3 months
- Age ≥18 years
- Willing and able to give informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| QEII Health Sciences Centre, Nova Scotia Health Coordinator of this site? Confirm its status | Halifax | Canada | Recruiting |
| Victoria Hospital, London Health Sciences Centre Coordinator of this site? Confirm its status | London | Canada | Recruiting |
| Westmount Kidney Care Centre Coordinator of this site? Confirm its status | London | Canada | Recruiting |
| Seven Oaks Hospital Chronic Disease Innovation Centre Inc. (CDIC) Coordinator of this site? Confirm its status | Winnipeg | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.